Scrip 100: Chugai USA's new CMO is a Man for All Regions
This article was originally published in Scrip
When the Swiss-born and transatlantic-bred Dr Athos Gianella-Borradori took up his new role as Chugai Pharma USA's chief medical officer in April, an international perspective was vital. So he took for his inspiration Carlos Goshn, the French-Lebanese-Brazilian businessman famous for turning round the Japanese car maker Nissan. As one of the first non-Japanese CEOs of a very traditional Japanese company, Goshn was the perfect role model in a job that would demand high levels of cultural awareness.
You may also be interested in...
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Two different outcomes for two different CD4/6 inhibitors – Eli Lilly’s Verzenio and Pfizer’s Ibrance – put the Lilly drug on track to be a new standard of care in high-risk early stage HR+, HER2-negative breast cancer. Novartis’s Kisqali could follow.